Latest in Amgen’s
Sort by
9 items
-
Amgen’s stock closes off lows to avoid worst day in 24 years as weight-loss-drug data underwhelms
Amgen’s MariTide achieved up to 20% weight loss in a mid-stage trial, but analysts were expecting up to 25%.Business - MarketWatch - 6 hours ago -
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.Business - CNBC - 21 hours ago -
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows
The drug, which is named MariTide and delivered in a monthly injection, is some time away from being sold.Business - The New York Times - 23 hours ago -
Amgen says no concerns around weight loss drug’s bone density data after stock falls
Analysts chewed over early data showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.Business - CNBC - November 13